Yeast Extract and Potassium Oxonate-Induced Hyperuricemia Model

Creative Bioarray offers a hyperuricemia model induced by yeast extract and potassium oxonate to meet the unique requirements of our clients. With our extensive expertise, our scientists are prepared to develop a comprehensive research plan specifically tailored to your needs. Furthermore, we provide services to evaluate the efficacy of your drug candidates.

Yeast extract, abundant in nucleic acids and proteins, has the potential to heighten the activity of xanthine oxidase (XOD). This increase in XOD activity leads to an amplified production of uric acid, consequently disrupting the normal purine metabolism process. In conjunction, potassium oxonate, classified as a triazabenzene compound, exerts its influence by suppressing the activity of uricase. This suppression further contributes to the escalation of uric acid levels within the body. The synergistic effect of yeast extract and potassium oxonate in inducing a model of hyperuricemia closely emulates the condition triggered by a high-purine diet in humans. This carefully designed model not only serves as a critical platform for assessing the effectiveness of various therapeutic interventions against hyperuricemia but also plays a pivotal role in unraveling the complex mechanisms that underpin this prevalent human condition.

Our Yeast Extract and Potassium Oxonate-Induced Hyperuricemia Model

• Available Animal

Rat

• Modeling Method

Animals are fed a daily regimen of yeast extract diet combined with intragastric potassium oxonate for 4 weeks to induce hyperuricemia.

Fig. 1 Modeling method of yeast extract and potassium oxonate-induced hyperuricemia model.

• Endpoints

• Serum biomarkers: uric acid (UA), creatinine, BUN, etc
• Kidney observation
• Histology analysis of kidney: H&E staining, Masson staining
• qPCR or Western blot
• Body weight
• Other customized endpoints: available upon request

Example Data

Fig. 2 Pathological changes in the renal tissue of six groups rats at experiment termination after YEP-potassium oxonate-induced hyperuricemia. (Li et al. 2022)

Quotation and Ordering

If you are interested in our hyperuricemia models, please feel free to contact us at any time or submit an inquiry to us directly. Our scientists are pleased to tailor the best-fit proposal to meet your demands.

References

1. Zhu, Y., et al. An update on the animal models in hyperuricaemia research. Clin Exp Rheumatol, 2017, 35(5): 860-864.
2. Li, Y., et al. Pharmacodynamic evaluation of the XOR inhibitor WN1703 in a model of chronic hyperuricemia in rats induced by yeast extract combined with potassium oxonate. Current Research in Pharmacology and Drug Discovery, 2022, 3: 100098.

Explore Other Options

• Alloxan-Induced Type 1 Diabetes Model
• Animal Model of Hyperuricemia
• High Fat Diet-Induced Obesity Model
• Nonalcoholic Fatty Liver Disease Model
• Type 1 Diabetes Mellitus Model

• Fructose and Potassium Oxonate-Induced Hyperuricemia Model
• Potassium Oxonate-Induced Hyperuricaemia Model

For research use only. Not for any other purpose.